Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announced completion of its pre-NDA consultation with China’s NMPA and its plans to submit an NDA for denifanstat in China SAN MATEO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metab ...

Sagimet Biosciences (NasdaqGM:SGMT) Conference October 21, 2025 07:00 AM ET Company ParticipantsDave Happel - CEOEduardo Martins - CMORob D’Urso - SVP of New ProductsConference Call ParticipantsNone - AnalystNoneGood day, everyone, and thank you very much for joining us at the H.C. Wainwright Liver Conference. Next up, we have a discussion with Sagimet Biosciences, and joining me from the Sagimet team is Dave Happel, CEO, Thierry Chauche, CFO, Rob D’Urso, SVP of New Products, and Eduardo Martins, CMO. Dave ...

Sagimet Biosciences Inc. (SGMT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ...

SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in three upcoming investor conferences. H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025, with a fireside chat available starting October 21 at 7am ET (link here).Guggenheim 2nd Annual Healthcare Innovation ...

Since my previous coverage on Sagimet Biosciences Inc (NASDAQ: SGMT ), the stock has traded a bit sideways, down just 2% over the past month. However, last month we got some very nice updates from management onI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the r ...

SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that analyses of the Phase 2b FASCINATE-2 study showing that denifanstat elicited fibrosis improvement in patients with advanced fibrosis will be presented at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2025, taking place November ...

Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are anticipated in the first half of 2026 SAN MATEO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has dosed the ...

SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced its participation in a drug development panel at Fierce Biotech Week taking place October 7-9, 2025 in Boston, MA. Panel Title:How Biotechs are Leveraging Artificial Intelligence (AI)/Machine Learning (ML) to Drive Efficiency and ROIPresenter: Marie O’Farrell, P ...

核心临床数据 - Denifanstat在治疗中重度痤疮的III期临床试验中达到所有主要和次要终点[1][3] - 该试验为随机、双盲、安慰剂对照、多中心临床研究，在中国纳入了480名患者，按1:1随机分组接受每日一次50mg Denifanstat或安慰剂，治疗周期为12周[3] - 与安慰剂相比，Denifanstat显示出186%的安慰剂校正治疗成功率提升，总皮损减少220%，炎性皮损减少202%[4] - 药物普遍耐受性良好[1][4] 产品管线与开发策略 - Denifanstat是一种每日一次口服的小分子脂肪酸合成酶抑制剂，由合作伙伴Ascletis在中国推进痤疮适应症的审批，公司则在全球其他地区开发其用于代谢功能障碍相关脂肪性肝炎[2] - 公司已启动第二款FASN抑制剂TVB-3567的首次人体I期临床试验，计划开发为中重度痤疮的新型疗法[5][7] - 公司领先候选药物Denifanstat用于MASH的IIb期临床试验FASCINATE-2已成功完成，并获得FDA突破性疗法认定，支持其进入后续开发阶段[6] 市场背景与医学会议 - 脂肪酸合成酶抑制代表了一种治疗痤疮的新作用机制，该疾病在美国每年影响超过5000万人，过去40年创新有限[5] - 关键临床数据在2025年欧洲皮肤病与性病学会大会上以口头报告形式发布，报告人为中国复旦大学华山医院皮肤科项蕾红教授[2][4] - 美国每年有510万痤疮患者接受皮肤科医生治疗，总市场规模超过5000万人，该疾病无法根治，多数患者需要长期管理和每年多次疗程以控制发作[8]

Sagimet Biosciences Inc. (SGMT) has been beaten down lately with too much selling pressure. While the stock has lost 15.8% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and ...